Results 61 to 70 of about 478,784 (306)
Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom
Introduction The use of oral anticancer medications has become more prevalent in cancer therapy. This is particularly the case in the management of advanced non-small cell lung cancer (NSCLC).
Joshua R. Coulter +8 more
doaj +1 more source
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily.
K. K. Laktionov +7 more
doaj +1 more source
Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley +1 more source
EGFR-positive CTCs correlates with worse prognosis.
A) EGFR-positive CTC enumeration from patients with colon, prostate and breast metastatic cancer (from Table 3); (Spearman rank correlation coefficient = 0.575 ...
Ana Vila (436509) +6 more
core +1 more source
Renalase is a recently discovered flavin adenine dinucleotide (FAD)-dependent soluble monoamine oxidase. It is expressed principally in the kidney, but its expression in the heart, brain, and skeletal muscle has also been confirmed.
Yasuko Yoshida +6 more
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma [PDF]
Background: Epidermal growth factor receptor mutations are predictive of the success of EGFR tyrosine kinase inhibitor treatment in patients with advanced non-small-cell lung cancer.
Nakamura, Yoichi +13 more
core +1 more source
Febriana M Puspita,1 Em Yunir,2 Putri S Agustina,1 Rani Sauriasari1 1Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; 2Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, IndonesiaCorrespondence: Rani ...
Puspita FM +3 more
doaj
Epigenetic reprogramming of lineage switching in cancer
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source
Introduction: Gefitinib is recently approved by the US Food and Drug Administration as a first-line treatment for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
林家齊;楊志新;李日翔 +1 more
core +1 more source

